Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- COO -14.2%, DOMO -12.9%, GCO -10.9%, HRL -7.6%, NTAP -7.3%, NTNX -6.9% (also increases share repurchase authorization by $350 mln; also collaboration with Finanz Informatik and signs long-term contract), BBWI -5.5%, CRWD -4.1% (also to acquire Onum), URBN -3.6%, VEEV -3.5%, LI -3.1%, NAT -2%, NVDA -1.8% (also approves additional $60 bln share repurchase authorization), HPQ -1.6%, BBY -1%
Other news:
- OTLK -69.6% (Provides regulatory update on FDA review of ONS-5010/LYTENAVA for the treatment of wet AMD)
- CGTX -15.7% (launches offering of 14.7 mln shares of common stock for gross proceeds of $30 mln)
- RR -6.9% (entered into new $100 mln At The Market offering agreement; terminated the prior ATM Agreement)
- SORA -2.8% (completed DV8 Public Company Limited tender offer)
- PRTA -1.9% (provides update on PRX012 and announces Phase 1 ASCENT results)
- VNDA -1.5% (FDA has granted Orphan Drug Designation for VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for the treatment of polycythemia vera)
- QGEN -1.4% (launches $750 mln Non-U.S. Convertible Bond offering due 2032)